Pfizer announces positive results from phase 3 TALAPRO─2 trial of Talzenna in combination with Xtandi in patients with ...
Pfizer Inc. announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an …